Drawing from US-based insights from Ipsos’ GLP-1 Impact Consumer Monitor, this report quantifies the impact of GLP-1s on alcohol consumption, profiles drinkers on GLP-1s versus those who aren't and explores attitudes, concerns, and behavioural shifts reshaping the consumer landscape.
GLP-1s are transforming the management of obesity – an area where consumers hold huge sway. Using insights from Ipsos' Consumer Obesity Monitor, assess ongoing anti-obesity medication & GLP-1 demand, track shifts in consumer expectations, and assess the impact of such treatments on their lifestyles.
Following the US approvals of the first indicated therapy for MASH in 2024 and Wegovy in August 2025, alongside extensive pipeline development, the treatment landscape is entering a period of significant change. Drawing on Ipsos’ MASH Therapy Monitor, this report provides a top-level view of the market landscape, patient profiles and treatment dynamics to support commercial and strategic planning.
As the heart failure landscape becomes increasingly complex and competitive, understanding differences across patient populations, treatment pathways and prescriber behaviour is critical. Combining real-world patient data with HCP perceptions, Ipsos’ Heart Failure Therapy Monitor provides a top-level view of the market landscape across HFpEF & HFrEF.
Through usage of GLP-1s, the obesity treatment landscape is undergoing massive transformation; treatment of several associated comorbid conditions with the same medications are also in the spotlight. This report – using Ipsos' Obesity & Cardiometabolic Therapy Monitor data - will help optimise strategies for those with both developmental or commercial interests in these fields.